TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Daiichi Sankyo, Inc.
DS1062-A-U303: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations
Eligible patients will be randomized 1:1:1 to receive treatment in one of the following arms: Arm A: Datopotamab Deruxtecan + Pembrolizumab + platinum chemotherapy Arm B: Datopotamab Deruxtecan + Pembrolizumab Arm C: Pembrolizumab + Pemetrexed + platinum chemotherapy
Datopotamab Deruxtecan (Dato-DXd) is a TROP2-directed antibody-drug conjugate.
For the first line treatment of patients with non-squamous non-small cell lung cancer and whose tumor expresses <50% PD-L1 TPS and has no actionable genetic mutation.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.